<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089479</url>
  </required_header>
  <id_info>
    <org_study_id>NO17629</org_study_id>
    <nct_id>NCT00089479</nct_id>
  </id_info>
  <brief_title>A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer</brief_title>
  <official_title>A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 2 arm study will compare the efficacy and safety of Taxotere + Xeloda, versus Taxotere
      alone, following a regimen of Adriamycin plus Cytoxan in women with high-risk breast cancer.
      Following 4 cycles of Adriamycin and Cytoxan, patients will be randomized to receive either
      1)Taxotere 75mg/m2 iv on day 1 and Xeloda 825mg/m2 po bid on days 1-14 of each 3 week cycle
      or 2) Taxotere 100mg/m2 iv alone on day 1 of each 3 week cycle. The anticipated time on study
      treatment is until disease progression, and the target sample size is 500+ individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival [Number of Events]</measure>
    <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
    <description>Number of patients with/without recurrence of breast cancer, or death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival [Time to Event]</measure>
    <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
    <description>Disease free survival was measured as the time from the date of randomization until the date of first event (recurrence of breast cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival [Number of Events]</measure>
    <time_frame>Time from the date of randomization to the date of death, or date last known to be alive. Patients were followed for an average of 5 years.</time_frame>
    <description>Number of patients who died/were alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival [Time to Event]</measure>
    <time_frame>Time from the date of randomization to the date of death, or date last known to be alive. Patients were followed for an average of 5 years.</time_frame>
    <description>Overall survival was measured as the time from the date of randomization to the date of death. Patients still alive at the time of the analysis were censored using the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast Cancer Free Survival [Number of Events]</measure>
    <time_frame>Time from the date of randomization to event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years .</time_frame>
    <description>Number of patients with/without recurrence of breast cancer, new primary breast cancer, or death related to the chemotherapy administered or due to breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast Cancer Free Survival [Time to Event]</measure>
    <time_frame>Time from the date of randomization to death, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
    <description>Breast cancer-free survival was measured as time from the date of randomization to the date of recurrence of breast cancer, new primary breast cancer, or death related to the chemotherapy administered or due to breast cancer. Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival Including New Primary Breast Cancer as Event [Number of Events]</measure>
    <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
    <description>Number of patients with/without recurrence of breast cancer, new primary breast cancer, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival Including New Primary Breast Cancer as Event [Time to Event</measure>
    <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
    <description>Time from the date of randomization until the date of first event (recurrence of breast cancer, new primary breast cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival Including Any New Cancer as Event [Number of Events]</measure>
    <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
    <description>Number of patients with/without recurrence of breast cancer, any new cancer, or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival Including Any New Cancer as Event [Time to Event]</measure>
    <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
    <description>Time from the date of randomization until the date of first event (recurrence of breast cancer, any new cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2611</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine [Xeloda]</intervention_name>
    <description>825mg/m2 po bid on days 1-14 of each 3 week cycle</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
    <description>75mg/m2 iv on day 1 of each 3 week cycle</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
    <description>100mg/m2 iv on day 1 of each 3 week cycle</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients 18-70 years of age;

          -  adenocarcinoma of the breast;

          -  previous invasive breast cancer if diagnosed &gt;5 years before entering study;

          -  no evidence of metastatic disease.

        Exclusion Criteria:

          -  history of severe hypersensitivity reaction to Taxotere;

          -  previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane;

          -  treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2004</study_first_submitted>
  <study_first_submitted_qc>August 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2004</study_first_posted>
  <results_first_submitted>March 31, 2011</results_first_submitted>
  <results_first_submitted_qc>May 24, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2011</results_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AC Then T</title>
          <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
        </group>
        <group group_id="P2">
          <title>AC Then XT</title>
          <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1304"/>
                <participants group_id="P2" count="1307"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1305">Safety Population (includes 19 patients randomized to ACXT, who received ACT)</participants>
                <participants group_id="P2" count="1283">Safety Population (includes 5 patients randomized to ACT, who received ACXT)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="973">total includes Completed and Alive in follow-up</participants>
                <participants group_id="P2" count="1018">total includes Completed and Alive in follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="331"/>
                <participants group_id="P2" count="289"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AC Then T</title>
          <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
        </group>
        <group group_id="B2">
          <title>AC Then XT</title>
          <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1304"/>
            <count group_id="B2" value="1307"/>
            <count group_id="B3" value="2611"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="8.81"/>
                    <measurement group_id="B2" value="50.6" spread="9.19"/>
                    <measurement group_id="B3" value="50.9" spread="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1304"/>
                    <measurement group_id="B2" value="1307"/>
                    <measurement group_id="B3" value="2611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival [Number of Events]</title>
        <description>Number of patients with/without recurrence of breast cancer, or death due to any cause.</description>
        <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
        <population>Intent−to−Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>AC Then T</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>AC Then XT</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival [Number of Events]</title>
          <description>Number of patients with/without recurrence of breast cancer, or death due to any cause.</description>
          <population>Intent−to−Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1140"/>
                    <measurement group_id="O2" value="1167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival [Number of Events]</title>
        <description>Number of patients who died/were alive.</description>
        <time_frame>Time from the date of randomization to the date of death, or date last known to be alive. Patients were followed for an average of 5 years.</time_frame>
        <population>Intent−to−Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>AC Then T</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>AC Then XT</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival [Number of Events]</title>
          <description>Number of patients who died/were alive.</description>
          <population>Intent−to−Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1196"/>
                    <measurement group_id="O2" value="1232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival [Time to Event]</title>
        <description>Disease free survival was measured as the time from the date of randomization until the date of first event (recurrence of breast cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
        <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
        <population>Intent−to−Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>AC Then T</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>AC Then XT</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival [Time to Event]</title>
          <description>Disease free survival was measured as the time from the date of randomization until the date of first event (recurrence of breast cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
          <population>Intent−to−Treat Population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median time to event based on Kaplan-Meier estimates was not reached in this adjuvant trial.</measurement>
                    <measurement group_id="O2" value="NA">The median time to event based on Kaplan-Meier estimates was not reached in this adjuvant trial.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival [Time to Event]</title>
        <description>Overall survival was measured as the time from the date of randomization to the date of death. Patients still alive at the time of the analysis were censored using the date they were last known to be alive.</description>
        <time_frame>Time from the date of randomization to the date of death, or date last known to be alive. Patients were followed for an average of 5 years.</time_frame>
        <population>Intent−to−Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>AC Then T</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>AC Then XT</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival [Time to Event]</title>
          <description>Overall survival was measured as the time from the date of randomization to the date of death. Patients still alive at the time of the analysis were censored using the date they were last known to be alive.</description>
          <population>Intent−to−Treat Population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median time to death based on Kaplan-Meier estimates was not reached in this adjuvant trial due to low death rate.</measurement>
                    <measurement group_id="O2" value="NA">The median time to death based on Kaplan-Meier estimates was not reached in this adjuvant trial due to low death rate.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breast Cancer Free Survival [Number of Events]</title>
        <description>Number of patients with/without recurrence of breast cancer, new primary breast cancer, or death related to the chemotherapy administered or due to breast cancer.</description>
        <time_frame>Time from the date of randomization to event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years .</time_frame>
        <population>Intent−to−Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>AC Then T</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>AC Then XT</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Cancer Free Survival [Number of Events]</title>
          <description>Number of patients with/without recurrence of breast cancer, new primary breast cancer, or death related to the chemotherapy administered or due to breast cancer.</description>
          <population>Intent−to−Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1146"/>
                    <measurement group_id="O2" value="1163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breast Cancer Free Survival [Time to Event]</title>
        <description>Breast cancer-free survival was measured as time from the date of randomization to the date of recurrence of breast cancer, new primary breast cancer, or death related to the chemotherapy administered or due to breast cancer. Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
        <time_frame>Time from the date of randomization to death, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
        <population>Intent−to−Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>AC Then T</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>AC Then XT</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Cancer Free Survival [Time to Event]</title>
          <description>Breast cancer-free survival was measured as time from the date of randomization to the date of recurrence of breast cancer, new primary breast cancer, or death related to the chemotherapy administered or due to breast cancer. Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
          <population>Intent−to−Treat Population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median time to event based on Kaplan-Meier estimates was not reached in this adjuvant trial.</measurement>
                    <measurement group_id="O2" value="NA">The median time to event based on Kaplan-Meier estimates was not reached in this adjuvant trial.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival Including New Primary Breast Cancer as Event [Number of Events]</title>
        <description>Number of patients with/without recurrence of breast cancer, new primary breast cancer, or death due to any cause.</description>
        <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
        <population>Intent−to−Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>AC Then T</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>AC Then XT</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival Including New Primary Breast Cancer as Event [Number of Events]</title>
          <description>Number of patients with/without recurrence of breast cancer, new primary breast cancer, or death due to any cause.</description>
          <population>Intent−to−Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1135"/>
                    <measurement group_id="O2" value="1153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival Including New Primary Breast Cancer as Event [Time to Event</title>
        <description>Time from the date of randomization until the date of first event (recurrence of breast cancer, new primary breast cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
        <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
        <population>Intent−to−Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>AC Then T</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>AC Then XT</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival Including New Primary Breast Cancer as Event [Time to Event</title>
          <description>Time from the date of randomization until the date of first event (recurrence of breast cancer, new primary breast cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
          <population>Intent−to−Treat Population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median time to event based on Kaplan-Meier estimates was not reached in this adjuvant trial.</measurement>
                    <measurement group_id="O2" value="NA">The median time to event based on Kaplan-Meier estimates was not reached in this adjuvant trial.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival Including Any New Cancer as Event [Number of Events]</title>
        <description>Number of patients with/without recurrence of breast cancer, any new cancer, or death due to any cause.</description>
        <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
        <population>Intent−to−Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>AC Then T</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>AC Then XT</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival Including Any New Cancer as Event [Number of Events]</title>
          <description>Number of patients with/without recurrence of breast cancer, any new cancer, or death due to any cause.</description>
          <population>Intent−to−Treat Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients without events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1104"/>
                    <measurement group_id="O2" value="1130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival Including Any New Cancer as Event [Time to Event]</title>
        <description>Time from the date of randomization until the date of first event (recurrence of breast cancer, any new cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
        <time_frame>Time from the date of randomization until the date of first event, or date last known to be event free if no event was reported. Patients were followed for an average of 5 years.</time_frame>
        <population>Intent−to−Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>AC Then T</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>AC Then XT</title>
            <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival Including Any New Cancer as Event [Time to Event]</title>
          <description>Time from the date of randomization until the date of first event (recurrence of breast cancer, any new cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.</description>
          <population>Intent−to−Treat Population</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1304"/>
                <count group_id="O2" value="1307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median time to event based on Kaplan-Meier estimates was not reached in this adjuvant trial.</measurement>
                    <measurement group_id="O2" value="NA">The median time to event based on Kaplan-Meier estimates was not reached in this adjuvant trial.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Length of study</time_frame>
      <desc>Safety Analysis Population: Patients are assigned to treatment groups based on the treatment (T or XT) they received, patients who did not receive T or X were assigned to the treatment groups as randomized. AE summaries display AEs that occurred during the period 1st study treatment intake (AC) until 30 days after last study treatment intake.</desc>
      <group_list>
        <group group_id="E1">
          <title>AC Then T</title>
          <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2; repeat every 3 weeks for 4 cycles</description>
        </group>
        <group group_id="E2">
          <title>AC Then XT</title>
          <description>Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 po (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="264" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>STOMATITIS ALL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ENTEROCUTANEOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>NON−CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>THROMBOSIS IN DEVICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>BREAST CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>BREAST INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>BREAST ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>FEBRILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>FUNGAL SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HISTOPLASMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MASTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MENINGITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PAROTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PERIDIVERTICULAR ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PLEURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PRIMARY ATYPICAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>COMPARTMENT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>METASTASES TO MENINGES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MENOMETRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PELVIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>VAGINAL LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ALVEOLITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PALMAR−PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>SKIN DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>BREAST PROSTHESIS USER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>BREAST RECONSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>LYMPHADENECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>NEOPLASM PROPHYLAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PROPHYLAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>SIMPLE MASTECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>AORTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>VENOUS OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1301" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1283" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="966" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="964" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="729" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="667" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="491" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="443" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="452" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="396" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1125" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1118" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>STOMATITIS ALL</sub_title>
                <counts group_id="E1" subjects_affected="848" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="980" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="581" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="759" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="618" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="591" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="552" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="596" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="289" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="389" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ORAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="1123" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1157" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="369" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="339" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="324" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="305" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="159" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL MYCOTIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="440" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="455" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="306" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="278" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="671" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="566" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="616" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="503" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="450" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="534" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="413" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="464" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="327" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="259" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="205" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="258" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="381" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="397" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="182" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="295" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="302" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="258" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="246" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="1113" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="1069" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="779" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="433" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="491" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="357" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="316" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="373" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="347" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="1283"/>
              </event>
              <event>
                <sub_title>LYMPHOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="1305"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="1283"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

